Background Diabetic macular oedema (DMO) is a common complication of diabetic
retinopathy. Although grid or focal laser photocoagulation has been shown to reduce the risk …

Intravitreal antivascular endothelial growth factor (anti-VEGF) treatment has drastically
improved the visual and anatomical outcomes in patients with diabetic macular edema …

Purpose Identification and characterization of patients with diabetic macular edema (DME)
are important for individualizing treatment and optimizing outcome. We investigated OCT …

Importance Some eyes have persistent diabetic macular edema (DME) following anti–
vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding …

Purpose To determine whether early visual acuity response to ranibizumab in diabetic
macular edema is associated with long-term outcome. Design Post hoc analysis of …

Objective To investigate baseline predictors of month 24 best-corrected visual acuity (BCVA)
and central foveal thickness (CFT) in patients with diabetic macular edema (DME) treated …

With the identification of novel targets, the number of interventional clinical trials in
ophthalmology has increased. Visual acuity has for a long time been considered the gold …

Diabetic macular oedema (DMO) is the major cause of visual impairment in people with
diabetes. Optical coherence tomography (OCT) is now the most widely used modality to …

Diabetic retinopathy and diabetic macular edema comprise a major source of visual
disability throughout the developed world. The etiology and pathogenesis of macular edema …

Purpose Assess associations of 2-year visual acuity (VA) outcomes with VA and optical
coherence tomography central subfield thickness (CST) after 12 weeks of anti–vascular …